Sub-Navigation

• Investor News
• Ad-hoc Publications
• Press
• Archive

Bayer Links

• Bayer Global
• Sustainability
• Press

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Investor News

Search

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR News via E-Mail, RSS Feed or SMS.

Friday May 16, 2008

Bayer and Onyx Announce Nexavar® Data Presentations at 44th American Society of Clinical Oncology (ASCO) Annual Meeting

Friday May 16, 2008

Phase III Asia-Pacific Study:

Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent

Trial Results Confirm Efficacy for Population Most Affected by the Disease

Thursday May 08, 2008

Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration

International study to evaluate efficacy and safety in treating a leading cause of blindness

Tuesday May 06, 2008

Bayer Schering Pharma to market new low-dose oral contraceptive YAZ® in Europe

Monday April 28, 2008

Bayer HealthCare and Regeneron Announce Encouraging 32-week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular Degeneration

Gains in visual acuity achieved in initial 12-week fixed dosing phase of study maintained in PRN (as-needed) dosing phase

Friday April 25, 2008

Werner Wenning at the Bayer AG Annual Stockholders' Meeting

"2007 was Bayer's most successful year to date"

Previous year's record levels and earnings targets exceeded / Dividend to be raised 35 percent to EUR 1.35 / Good start to fiscal 2008 / Bayer Climate Program being implemented and expanded

Thursday April 24, 2008

Interim report for the first quarter of 2008

Bayer off to an excellent start in 2008

Sales up 2.4 percent to EUR 8,536 million / EBITDA before special items up 9.8 percent to EUR 2,185 million / EBIT before special items up 8.9 percent to EUR 1,497 million / Full-year guidance for CropScience raised / Positive Group forecast confirmed

Monday April 21, 2008

Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin®

Wednesday April 02, 2008

Bayer HealthCare Affiliate MEDRAD Announces Completion of Subsequent Offering Period for Shares of Possis Medical

Merger to Be Completed Shortly

Monday March 31, 2008

Bayer appeals invalidity ruling on its Yasmin® Patent

Appeal will be heard by the Federal Circuit

Wednesday March 26, 2008

Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period

Subsequent Offering Period Expires on Tuesday, April 1, 2008

Tuesday March 11, 2008

Bayer HealthCare to acquire OTC Business of Sagmel, Inc.

Acquisition strengthens Bayer Consumer Care's Presence in Eastern Europe

Monday March 03, 2008

Court decides against Bayer's Yasmin® patent

Bayer HealthCare margin target (EBITDA before special items) for 2008 slightly adjusted - margin target for 2009 remains unchanged / Company will consider its legal options

Thursday February 28, 2008

Spring Financial News Conference:

Wenning: 2007 was Bayer's most successful year to date

Sales grew 11.8 percent to EUR 32,385 million / EBITDA before special items advanced 21.4 percent to EUR 6,777 million / Performance target for 2007 exceeded: underlying EBITDA margin of 20.9 percent / EBIT before special items climbed 23.2 percent to EUR 4,287 million / Group net income totaled EUR 4,711 million - boosted by divestiture proceeds / Further earnings increase expected for 2008

Tuesday February 26, 2008

Bayer proposes increased dividend for 2007 of EUR 1.35 per share

Wednesday February 20, 2008

Bayer will vigorously defend itself against Kogenate patent infringement suit filed by Novartis

Monday February 18, 2008

Bayer and Onyx Provide Update on Phase III Trial of Nexavar® in Patients with Non-Small Cell Lung Cancer

Monday February 11, 2008

Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement

Monday January 28, 2008

Nexavar® Approved for the Treatment of Kidney Cancer in Japan

First approved oral targeted therapy for metastatic RCC in Japan

Thursday January 24, 2008

Bayer extends product portfolio for liver cancer patients in Japan

Japanese authorities grant priority review status for Nexavar® in liver cancer / Launch of liver-specific contrast agent Primovist® in Japan

Wednesday January 23, 2008

Bayer establishes US special access program for Leukine® while replacing current liquid formulation

Leukine lyophilized formulation temporarily reserved for patients with Acute Myelogenous Leukemia (AML) and those experiencing bone marrow transplantation graft failure or engraftment delay / Bayer will replace current 500 mcg liquid formulation; aims to restore US supplies of Leukine to current levels as quickly as possible

Thursday January 17, 2008

US Food and Drug Administration Approves RECOTHROM

Wednesday January 09, 2008

A new high-potential biofuel crop

Archer Daniels Midland Company, Bayer CropScience and Daimler to cooperate in Jatropha biodiesel project

Thursday January 03, 2008

B-cell chronic lymphocytic leukemia (B-CLL):

Expanded Labeling for MabCampath® in Europe